Objective:To systematically evaluate the clinical efficacy and safety of Tanreqing injection in the treatment of heart failure complicated with pulmonary infection.Methods:The database of CNKI,SinoMed,VIP full text da...Objective:To systematically evaluate the clinical efficacy and safety of Tanreqing injection in the treatment of heart failure complicated with pulmonary infection.Methods:The database of CNKI,SinoMed,VIP full text database,Wanfang database,Cochrance Library,Web of Science and PubMed were searched.The retrieval time was from the inception to August 2021.Clinical randomized controlled trial of Tanreqing injection in the treatment of heart failure complicated with pulmonary infection was collected,and two researchers independently screened the document data.Meta-analysis was performed using RevMan 5.4.1 software.Results:A total of 10 documents were included,including 862 cases of heart failure complicated with pulmonary infection,including 431 cases in the test group,and 431 cases in the control group.The Meta analysis showed that compared to the control group,the test group increased clinical efficiency[OR=4.56,95%CI(2.79,7.52),P<0.00001],reduced the value of C-reactive protein[MD=-7.55,95%CI(-11.40,-3.69),P=0.0001],reduced the time required to correct heart failure[OR=-4.04,95%CI(-4.59,-3.49),P<0.00001],reduced the number of days of the average hospitalization[MD=-4.78,95%CI(-6.67,-2.89),P<0.00001],and there were no statistically significant differences in the incidence of adverse reactions.Conclusion:Tanreqing injection,as an auxiliary treatment for heart failure complicated with pulmonary infection,has significantly effective effect on improving efficiency.Tanreqing injection has a certain advantage in reducing C-creative protein values,shortening the time of correcting heart failure,and reducing the number of days of the average hospitalization,and the adverse reactions are smaller.However,the overall quality of the included studies is low,and more high-quality randomized controlled trials are needed to increase the evidence-based basis.展开更多
Objective:To study the effect of Azithromycin sequential therapy combined with Tanreqing injection on serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α in children with mycoplasma pneumonia.Methods:A total of 80 childre...Objective:To study the effect of Azithromycin sequential therapy combined with Tanreqing injection on serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α in children with mycoplasma pneumonia.Methods:A total of 80 children with mycoplasma pneumonia in our hospital from June 2014 to September 2016 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group were treated with Azithromycin sequential therapy, the treatment group were treated with Azithromycin sequential therapy combined with Tanreqing injection. The two groups were treated for 2 periods. The serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α levels of the two groups before and after treatment were compared.Results: There were no significantly differences of the serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α levels of the two groups before treatment. The serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α levels of the two groups after treatment were significantly lower than before treatment, and that of the treatment group were significantly lower than the control group.Conclusion:Azithromycin sequential therapy combined with Tanreqing injection can significantly reduce the serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α levels of children with mycoplasma pneumonia, have good clinical efficacy, and it was worthy clinical application.展开更多
Objective To explore the neuroprotective effects and mechanism of Tanreqing Injection(TRQ)on treating ischemic stroke based on network pharmacology and in vivo experimental validation.Methods The chemical compounds of...Objective To explore the neuroprotective effects and mechanism of Tanreqing Injection(TRQ)on treating ischemic stroke based on network pharmacology and in vivo experimental validation.Methods The chemical compounds of TRQ were retrieved based on published data,with targets retrieved from PubChem,Therapeutic Target Database and DrugBank.Network visualization and analysis were performed using Cytoscape,with protein-protein interaction networks derived from the STRING database.Enrichment analysis was performed using Kyoto Encyclopedia of Genes Genomes pathway and Gene Ontology analysis.In in vivo experiments,the middle cerebral artery occlusion(MCAO)model was used.Infarct volume was determined by 2,3,5-triphenyltetrazolium hydrochloride staining and protein expressions were analyzed by Western blot.Molecular docking was performed to predict ligand-receptor interactions.Results We screened 81 chemical compounds in TRQ and retrieved their therapeutic targets.Of the targets,116 were therapeutic targets for stroke.The enrichment analysis showed that the apelin signaling pathway was a key pathway for ischemic stroke.Furthermore,in in vivo experiment we found that administering with intraperitoneal injection of 2.5 mL/kg TRQ every 6 h could significantly reduce the infarct volume of MCAO rats(P<0.05).In addition,protein levels of the apelin receptor(APJ)/phosphatidylinositol 3-kinase(PI3K)/protein kinase B(AKT)pathway were increased by TRQ(P<0.05).In addition,41 chemical compounds in TRQ could bind to APJ.Conclusions The neuroprotective effect of TRQ may be related to the APJ/PI3K/AKT signaling pathway.However,further studies are needed to confirm the findings.展开更多
【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMe...【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。展开更多
基金National Natural Science Foundation of China(No.81573817)。
文摘Objective:To systematically evaluate the clinical efficacy and safety of Tanreqing injection in the treatment of heart failure complicated with pulmonary infection.Methods:The database of CNKI,SinoMed,VIP full text database,Wanfang database,Cochrance Library,Web of Science and PubMed were searched.The retrieval time was from the inception to August 2021.Clinical randomized controlled trial of Tanreqing injection in the treatment of heart failure complicated with pulmonary infection was collected,and two researchers independently screened the document data.Meta-analysis was performed using RevMan 5.4.1 software.Results:A total of 10 documents were included,including 862 cases of heart failure complicated with pulmonary infection,including 431 cases in the test group,and 431 cases in the control group.The Meta analysis showed that compared to the control group,the test group increased clinical efficiency[OR=4.56,95%CI(2.79,7.52),P<0.00001],reduced the value of C-reactive protein[MD=-7.55,95%CI(-11.40,-3.69),P=0.0001],reduced the time required to correct heart failure[OR=-4.04,95%CI(-4.59,-3.49),P<0.00001],reduced the number of days of the average hospitalization[MD=-4.78,95%CI(-6.67,-2.89),P<0.00001],and there were no statistically significant differences in the incidence of adverse reactions.Conclusion:Tanreqing injection,as an auxiliary treatment for heart failure complicated with pulmonary infection,has significantly effective effect on improving efficiency.Tanreqing injection has a certain advantage in reducing C-creative protein values,shortening the time of correcting heart failure,and reducing the number of days of the average hospitalization,and the adverse reactions are smaller.However,the overall quality of the included studies is low,and more high-quality randomized controlled trials are needed to increase the evidence-based basis.
文摘Objective:To study the effect of Azithromycin sequential therapy combined with Tanreqing injection on serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α in children with mycoplasma pneumonia.Methods:A total of 80 children with mycoplasma pneumonia in our hospital from June 2014 to September 2016 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group were treated with Azithromycin sequential therapy, the treatment group were treated with Azithromycin sequential therapy combined with Tanreqing injection. The two groups were treated for 2 periods. The serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α levels of the two groups before and after treatment were compared.Results: There were no significantly differences of the serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α levels of the two groups before treatment. The serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α levels of the two groups after treatment were significantly lower than before treatment, and that of the treatment group were significantly lower than the control group.Conclusion:Azithromycin sequential therapy combined with Tanreqing injection can significantly reduce the serum sTREM-1, CK, G-CSF, IL-10, CRP and TNF-α levels of children with mycoplasma pneumonia, have good clinical efficacy, and it was worthy clinical application.
文摘Objective To explore the neuroprotective effects and mechanism of Tanreqing Injection(TRQ)on treating ischemic stroke based on network pharmacology and in vivo experimental validation.Methods The chemical compounds of TRQ were retrieved based on published data,with targets retrieved from PubChem,Therapeutic Target Database and DrugBank.Network visualization and analysis were performed using Cytoscape,with protein-protein interaction networks derived from the STRING database.Enrichment analysis was performed using Kyoto Encyclopedia of Genes Genomes pathway and Gene Ontology analysis.In in vivo experiments,the middle cerebral artery occlusion(MCAO)model was used.Infarct volume was determined by 2,3,5-triphenyltetrazolium hydrochloride staining and protein expressions were analyzed by Western blot.Molecular docking was performed to predict ligand-receptor interactions.Results We screened 81 chemical compounds in TRQ and retrieved their therapeutic targets.Of the targets,116 were therapeutic targets for stroke.The enrichment analysis showed that the apelin signaling pathway was a key pathway for ischemic stroke.Furthermore,in in vivo experiment we found that administering with intraperitoneal injection of 2.5 mL/kg TRQ every 6 h could significantly reduce the infarct volume of MCAO rats(P<0.05).In addition,protein levels of the apelin receptor(APJ)/phosphatidylinositol 3-kinase(PI3K)/protein kinase B(AKT)pathway were increased by TRQ(P<0.05).In addition,41 chemical compounds in TRQ could bind to APJ.Conclusions The neuroprotective effect of TRQ may be related to the APJ/PI3K/AKT signaling pathway.However,further studies are needed to confirm the findings.
文摘【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。
